Xilio Therapeutics
32 hedge funds and large institutions have $51M invested in Xilio Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 0 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
19% more capital invested
Capital invested by funds: $42.8M → $51M (+$8.14M)
14% more funds holding
Funds holding: 28 → 32 (+4)
0.04% more ownership
Funds ownership: 4.14% → 4.18% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$244K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$225K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$56.1K |
| 4 |
Morgan Stanley
New York
|
+$15.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$12.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$57.4K |
| 2 |
Millennium Management
New York
|
-$31.8K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$18.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NL
26
NWAM LLC
Mercer Island,
Washington
| $31.7K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $15K | +$1.05K | +24 | +8% |
|
28
JP Morgan Chase
New York
| $9K | – | – | – |
|
|
KFI
29
Key Financial Inc
West Chester,
Pennsylvania
| $2.63K | +$2.59K | +59 | New |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$2.28K | +52 | New |
|
31
UBS Group
Zurich,
Switzerland
| $637 | – | – | – |
|
32
Wells Fargo
San Francisco,
California
| $247 | – | – | – |
|
XLO Hedge Fund Activity: Q1 2023 in Review
32 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2023, worth a combined $51M — up 19% from $42.8M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XLO positions and 0 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Rock Springs Capital Management, adding an estimated $244K. The largest seller was Renaissance Technologies, cutting an estimated $57.4K.
- 32 institutional investors held Xilio Therapeutics (XLO) as of Q1 2023, up from 28 in Q4 2022.
- Funds reported $51M of Xilio Therapeutics stock for Q1 2023, up 19% quarter-over-quarter.
- 4 funds opened new Xilio Therapeutics positions in Q1 2023 and 0 closed out, a net change of +4 holders.
- The largest Xilio Therapeutics buyer in Q1 2023 was Rock Springs Capital Management, an estimated $244K added.
- The largest Xilio Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $57.4K sold.
Based on aggregated 13F filings for Q1 2023.